Cover Image

Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis

Background Advances in targeted therapies have expanded the treatment options for colorectal cancer (CRC), allowing for more tailored and effective approaches to managing the disease. In targeted therapy, Bevacizumab is a commonly prescribed anti-VEGF monoclonal antibody that has a direct anti-vascu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tehnia Naz (Author), Anees ur Rehman (Author), Aleena Shahzad (Author), Muhammad Fawad Rasool (Author), Zikria Saleem (Author), Rabia Hussain (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
by: Assia Konsoulova, et al.
Published: (2016)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018)

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Ningning Liu, et al.
Published: (2020)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
by: Deyan Davidov
Published: (2014)

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center
by: Călin Căinap, et al.
Published: (2021)

Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
by: Zhuoling Zheng, et al.
Published: (2024)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018)

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
by: Romero-Lorca A, et al.
Published: (2021)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020)

Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
by: Xinyi Xu, et al.
Published: (2022)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014)

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
by: Thérèse H Franco, et al.
Published: (2008)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST - LINE CHEMOTHERAPY
by: Deyan Davidov
Published: (2017)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023)

Gastrointestinal perforations in a patient treated by Bevacizumab and chemotherapy: Is it an anaphylactic reaction?
by: Wen-Ling Lee, et al.
Published: (2020)

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022)

Assessing Knowledge and Perception Regarding Antimicrobial Stewardship and Antimicrobial Resistance in University Students of Pakistan: Findings and Implications
by: Iltaf Hussain, et al.
Published: (2021)

Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer
by: Camillo Porta
Published: (2011)

Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy
by: Alexander Hendricks, et al.
Published: (2020)

Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
by: Soshi Kusunoki, et al.
Published: (2018)

Risk Factors Associated With Medication Errors Among Patients Suffering From Chronic Disorders
by: Muhammad Fawad Rasool, et al.
Published: (2020)

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
by: Shin S, et al.
Published: (2018)

Tests employed in the psychometric validation of the Insulin Treatment Appraisal Scale (ITAS) in T2DM patients; a systematic review of the literature
by: Saba Rasheed, et al.
Published: (2024)

Immunotherapy regimens for metastatic colorectal carcinomas
by: Babar Bashir, et al.
Published: (2018)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
by: Rose Isono-Nakata, et al.
Published: (2018)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015)

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
by: Carlotta Defferrari, et al.
Published: (2012)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
by: Jianling Bi, et al.
Published: (2021)

Molecularly targeted drugs for metastatic colorectal cancer
by: Cheng YD, et al.
Published: (2013)

Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report
by: Aram A. Musaelyan, et al.
Published: (2024)

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
by: Anna Maria Rachiglio, et al.
Published: (2020)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024)

Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases
by: Francesco Erovigni, et al.
Published: (2016)

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US
by: Victoria Federico Paly, et al.
Published: (2024)

The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis
by: Anees ur Rehman, et al.
Published: (2023)